(1) Background: Human exposure to organophosphorus compounds employed as pesticides or as chemical warfare agents induces deleterious effects due to cholinesterase inhibition. One therapeutic approach is the reactivation of inhibited acetylcholinesterase by oximes. While currently available oximes are unable to reach the central nervous system to reactivate cholinesterases or to display a wide spectrum of action against the variety of organophosphorus compounds, we aim to identify new reactivators without such drawbacks. (2) Methods: This study gathers an exhaustive work to assess in vitro and in vivo efficacy, and toxicity of a hybrid tetrahydroacridine pyridinaldoxime reactivator, KM297, compared to pralidoxime. (3) Results: Blood–brain barrier crossing assay carried out on a human in vitro model established that KM297 has an endothelial permeability coefficient twice that of pralidoxime. It also presents higher cytotoxicity, particularly on bone marrow-derived cells. Its strong cholinesterase inhibition potency seems to be correlated to its low protective efficacy in mice exposed to paraoxon. Ventilatory monitoring of KM297-treated mice by double-chamber plethysmography shows toxic effects at the selected therapeutic dose. This breathing assessment could help define the No Observed Adverse Effect Level (NOAEL) dose of new oximes which would have a maximum therapeutic effect without any toxic side effects.
In the absence of appropriate medical care, exposure to organophosphorus nerve agents, such as VX, can lead to respiratory failure, and potentially death by asphyxiation. Despite the critical role of respiratory disturbances in organophosphorus-induced toxicity, the nature and underlying mechanisms of respiratory failure remain poorly understood. This study aimed to characterize respiratory alterations by determining their type and duration in mice exposed to a subcutaneous sublethal dose of VX. Respiratory ventilation in Swiss mice was monitored using dual-chamber plethysmography for up to 7 days post-exposure. Cholinesterase activity was assessed via spectrophotometry, and levels of inflammatory biomarkers were quantified using Luminex technology in blood and tissues involved in respiration (diaphragm, lung, and medulla oblongata). Additionally, a histological study was conducted on these tissues to ensure their structural integrity. Ventilatory alterations appeared 20-25 minutes after the injection of 0.9 LD50 VX and increased until the end of the recording, i.e., 40 minutes after intoxication. Concurrent with the occurrence of apnea, increased inspiratory and expiratory times resulted in a significant decrease in respiratory rate in exposed mice compared to controls. Ventilatory amplitude and, consequently, minute volume were reduced, while specific airway resistance significantly increased, indicating bronchoconstriction. These ventilatory effects persisted up to 24 or even 72 hours post-intoxication, resolving on the 7th day. They were correlated with a decrease in acetylcholinesterase activity in the diaphragm, which persisted for up to 72 hours, and with the triggering of an inflammatory reaction in the same tissue. No significant histologic lesions were observed in the examined tissues. The ventilatory alterations observed up to 72 hours post-VX exposure appear to result from a functional failure of the respiratory system rather than tissue damage. This comprehensive characterization contributes to a better understanding of the respiratory effects induced by VX exposure, which is crucial for developing specific medical countermeasures.
The chemical risk associated with the use of organophosphorus nerve agents remains a major concern, as highlighted by recent international events (e.g., Syrian conflict, Novichok poisoning incidents) and the tense geopolitical climate. Concurrently, the use of organophosphorus pesticides continues to represent a major global public health challenge, resulting in numerous poisonings and fatalities each year. Organophosphorus compounds exert their toxic effects by irreversibly inhibiting cholinesterase enzymes, disrupting cholinergic signaling within the affected organism. This disruption impairs vital functions and, without appropriate medical intervention, can result in respiratory failure and death. However, whether differences in the molecular and physiological mechanisms underlying organophosphorus compound-induced respiratory failure between pesticides and nerve agents exist remains poorly defined. This study aimed to characterize and compare respiratory toxicity in mice exposed to two sublethal organophosphorus compounds: a pesticide (paraoxon) and a sarin structural analog (NIMP). Respiratory ventilation in mice was monitored using double-chamber plethysmography. Cholinesterase activity and inflammatory biomarkers were quantified in blood and tissues involved in respiration. Both compounds dose-dependently affected ventilatory function of the mice, reducing respiratory rate and minute volume and increasing specific airway resistance. No significant differences were observed between the two organophosphorus compounds in these effects. However, lungs and diaphragm triggered a rapid inflammatory response, depending on the specific organophosphorus compound tested. While NIMP exposure increased IL-6 expression, potentially involving the NF-κB pathway, POX exposure upregulated IL-1ß expression without activating NF-κB. Thus, exposure to POX or NIMP similarly impaired ventilatory function in mice, but distinct signaling pathways appear to be involved.